Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Triple-negative Breast Cancer
100%
TIMP-2
100%
Breast Cancer Treatment
100%
Matrix metalloproteinase-9 (MMP-9)
44%
Enhanced Selectivity
22%
Engineered Protein
22%
Human Proteins
11%
Binding Activity
11%
Surface Display
11%
Integrin Binding
11%
Highly Selective
11%
Protein Therapeutics
11%
Transgenic
11%
Targeted Treatment
11%
Cellular Invasion
11%
Antitarget
11%
Cancer Progression
11%
Enhanced Activity
11%
Therapeutic Approaches
11%
Computational Design
11%
X-ray Crystallography
11%
MMP-9 Inhibitor
11%
Invasion/metastasis
11%
Metastatic Breast Cancer
11%
Breast Cancer Progression
11%
MMP Inhibitors
11%
Tumor Growth Inhibition
11%
Patient-derived Xenograft
11%
Structural Insights
11%
Engineered Variants
11%
Integrin
11%
Tumor Invasion
11%
Tumor Angiogenesis
11%
Biomarkers of Response
11%
Therapeutic Strategies
11%
Yeast Surface Display
11%
Therapeutic Potential
11%
Tumor Growth
11%
Cancer Therapy
11%
Novel Proteins
11%
Pharmacology, Toxicology and Pharmaceutical Science
Tissue Inhibitor of Metalloproteinase 2
100%
Triple Negative Breast Cancer
100%
Gelatinase B
55%
Enzymes
22%
Integrin
22%
Cancer Growth
22%
Tumor Growth
22%
Antitarget
11%
Malignant Neoplasm
11%
Biological Marker
11%
Biochemistry, Genetics and Molecular Biology
Metalloprotease Inhibitor
100%
MMP9
55%
Gelatinase B
55%
Engineered Proteins
22%
Tumor Progression
22%
Integrin
22%
Enzyme
22%
Binding Affinity
11%
Angiogenesis
11%
Transgenics
11%
X-Ray Crystallography
11%